Novartis Investigative Site

Baotou, Inner Mongolia 014040

1 studies enrolling now · 10 studies all time

What they study most

Acute Heart Failure, Atherosclerosis, Autoimmunity, Inflammation, Cardiovascular Disease and Lipoprotein(a), Relapsing Multiple Sclerosis, Resistant Hypertension, Sjogren Syndrome, Sjogrens Syndrome

Studies at this site

• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• Secukinumab Open Label Roll-over Extension Protocol — Recruiting now
• A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. — Running, not enrolling
• Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome — Completed
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Global Non-interventional Heart Failure Disease Registry — Stopped early